Vol 9: Ranibizumab versus Bevacizumab for Ophthalmic Diseases Related to Neovascularisation: A Meta-Analysis of Randomised Controlled Trials.Reportar como inadecuado



 Vol 9: Ranibizumab versus Bevacizumab for Ophthalmic Diseases Related to Neovascularisation: A Meta-Analysis of Randomised Controlled Trials.


Vol 9: Ranibizumab versus Bevacizumab for Ophthalmic Diseases Related to Neovascularisation: A Meta-Analysis of Randomised Controlled Trials. - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Descargar gratis o leer online en formato PDF el libro: Vol 9: Ranibizumab versus Bevacizumab for Ophthalmic Diseases Related to Neovascularisation: A Meta-Analysis of Randomised Controlled Trials.
This article is from PLoS ONE, volume 9.AbstractBackground: Bevacizumab is believed to be as effective and safe as ranibizumab for ophthalmic diseases; however, its magnitude of effectiveness and safety profile remain controversial. Thus, a meta-analysis and systematic review appears necessary. Methods: PubMed and EMBASE were systematically searched with no restrictions. All relevant citations comparing ranibizumab and bevacizumab were considered for inclusion. Pooled effect estimates were obtained using a fixed- and random-effects meta-analysis. Results: Nine independent randomised-controlled clinical trials RCTs involving 2,289 participants were identified. Compared with bevacizumab, the overall combined weighted mean difference WMD of the mean change in visual acuity for ranibizumab was 0.52 letters 95% CI −0.11–1.14. The odds ratios ORs of gaining ≥15, gaining 5–14, losing 5–14 and losing ≤15 letters were 1.10 95% CI 0.90–1.33, 0.93 95% CI 0.77–1.11, 0.89 95% CI 0.65–1.22 and 0.95 95% CI 0.73–1.25, respectively. The risk of serious systemic events increased by 17% 95% CI 6%–27%, p = 0.0042 for bevacizumab treatment in comparison with ranibizumab. No statistically significant differences between the two treatments were found for the nonfatal arterial thrombotic events, ocular serious adverse, death from vascular and all causes events. Conclusions: Bevacizumab is not inferior to ranibizumab as a treatment for achieving visual acuity. The use of bevacizumab was associated with an increased risk of developing serious systemic events. Weighing the costs and health outcomes is necessary when selecting between bevacizumab and ranibizumab for ophthalmic diseases. Due to the limitations of the available data, further research is needed.



Autor: Wu, Bin; Wu, Haixiang; Liu, Xiaoyan; Lin, Houwen; Li, Jin

Fuente: https://archive.org/







Documentos relacionados